Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)

NCT04518735 | Completed

• 1 other identifier: IIBSP-COV-2020-24
• Study Type: observational
• Target: 1,707
• Locations: 1 country
• Sites: 1

Brief Summary

CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents who are admitted to the hospital for COVID-19 compared with patients who do not receive anticoagulants or antiplatelet agents.

Conditions

Covid19

Keywords

Covid19; Oral anticoagulant; VKA; DOAC; Antiplatelet therapy; Heparin; Low molecular-weight heparin

Outcome Measures

Primary Outcomes (2)

• Mortality

  From hospital admission to day 28

• Transfer to the Intensive Care Unit (ICU)

  From hospital admission to day 28

Secondary Outcomes (2)

• Thromboembolic complications

  From hospital admission to day 28

• Major bleeding complications

  From hospital admission to day 28

Study Arms (3)

Patients on previous oral anticoagulant treatment

Patients receiving chronic anticoagulation with vitamin K antagonists (VKA, warfarin or acenocumarol) or with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for any indication

Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19

Patients on previous antiplatelet therapy

Patients receiving chronic antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamol) for any indication

Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19

Patients without antithrombotic therapy

Patients receiving nor chronic oral anticoagulation neither chronic antiplatelet therapy

Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19

Interventions

Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19 OTHER

Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy

Patients on previous antiplatelet therapy; Patients on previous oral anticoagulant treatment; Patients without antithrombotic therapy

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients of any age and sex, suffering from Covid19 needing hospital admission more than 1 day for treatment and/or supportive care

You may qualify if:

• Patient admitted for COVID-19 at the Hospital de la Santa Creu i Sant Pau,
• Positive COVID-19 polymerase chain reaction test
• Length of stay more than 24 hours

You may not qualify if:

• No objective diagnose for COVID-19
• Outpatient
• Lenght of stay less than 24hours

Sponsors & Collaborators

• Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau: lead

Study Sites (1)

Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, 08025, Spain

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 18, 2020
• First Posted: August 19, 2020
• Study Start: April 1, 2020
• Primary Completion: June 30, 2020
• Study Completion: June 30, 2020
• Last Updated: August 19, 2020

Record last verified: 2020-08

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)